The Food and Drug Administration on Monday granted a key approval for AstraZeneca and Daiichi Sankyo’s Enhertu, clearing a regimen involving the drug as an initial treatment for HER2-positive breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback